Postmenopausal hormone therapy and asthma onset in the E3N cohort
Oestrogen-only hormone replacement therapy (HRT) may increase the risk of developing asthma after the menopause, suggests a large scale study published ahead of print in the journal Thorax.
The authors base their findings on 57, 664 women, who were quizzed about their use of HRT and development of asthma symptoms every two years between 1990 and 2002.
All the women were taking part in the French E3N study, which includes almost 100, 000 women born between 1925 and 1950, and is the French component of the European Prospective Investigation into Cancer and Nutrition (EPIC).
None of these women had asthma when menopausal symptoms began.
The monitoring period equated to 495,448 person years in all, of which over a third was accounted for by women who had not used HRT (35.7%).
Previous users made up 4.5% while information on how long HRT was used was not known for a further 4%. Of the remainder, just under 56% were recent users of HRT.
Between 1990 and 2002, 569 women were newly diagnosed with asthma, corresponding to a rate of 1.15 cases per 1000 women a year.
Compared with women who had never used any form of HRT, those who did use it were 21% more likely to develop asthma, after adjusting for factors likely to influence the results.
Almost one in 10 women with a natural menopause (9.4%), and more than one in four (28%) of those with a surgically induced menopause, used HRT containing oestrogen alone.
The risk of asthma was significant only among those using oestrogen alone. Among these women the overall risk of asthma was 54% higher than among those who had never used any form of HRT.
Oestrogen only users who had never smoked and those who had had some form of allergy before their asthma diagnosis were at greatest risk of developing asthma- 80% and 86% higher, respectively.